Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-06-05
1999-03-16
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548486, A61K 3140, C07D20934
Patent
active
058831169
ABSTRACT:
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
REFERENCES:
patent: 2872372 (1959-02-01), Hull
patent: 2968557 (1961-01-01), Burgardt et al.
patent: 4642309 (1987-02-01), Michel et al.
patent: 4826847 (1989-05-01), Michel et al.
patent: 4853403 (1989-08-01), Shiraishi et al.
patent: 4868304 (1989-09-01), Larock et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5051417 (1991-09-01), Nadler et al.
patent: 5057538 (1991-10-01), Shiraishi et al.
patent: 5089516 (1992-02-01), Shiraishi et al.
patent: 5124347 (1992-06-01), Conner et al.
patent: 5202341 (1993-04-01), Shiraishi et al.
patent: 5206261 (1993-04-01), Kawaguchi et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5322950 (1994-06-01), Sircar et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5374652 (1994-12-01), Buzzetti et al.
patent: 5382593 (1995-01-01), Le Baut et al.
patent: 5397787 (1995-03-01), Buzzetti et al.
patent: 5409949 (1995-04-01), Buzzetti et al.
patent: 5463052 (1995-10-01), Haga et al.
Translation of Simonnot et al., "Process for Dyeing Textile Materials Made From Polyacrylonitrile" Imperial Chemical Industries Ltd. 1-8 Patent Specification (1965).
Translation of Neber et al., "On the action of Benzaldehydes on the Free Aminophenylacetic Acid (II)" Chem. Institute of the Univ. of Tubingen 1-8 (1923).
Translation of Szanatay et al., "Process for Preparing Spiro-oxindole Derivatives and of Drug Preparation Containing Same" 1-29 (1992).
Beilstein Reg. No.: 252929 Beilstein (1923). Cytotoxic Activity of 3-(2-Chloro-30Indolylmethlene) 1,3-Dihydroindol-2-Ones," AntiCancer Research 16:3585-3588 (1996).
Terrett et al., "Combinatorial Synthesis-The Design of Compound Libraries and their Application to Drug Discovery," Tetrahedron 51(30):8135-8173 (1995).
Coda et al., "3-(4-methylbenziliden)-1,3-dihydroindol-2-one," Journal of the Chemical Society, Perkin Transactions 2 4:615-620 (1984), Database Crossfire, Beilstein No. 6-21.
Wahl, "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," Ann. Chim p. 350 (1926), Database Crossfire, Beilstein No. 2-21-00-00290.
Elliot, "1-methyl-2-(3-oxinodolidenmethyl)-pyridinium," Journal of Organic Chemistry 29:2438-2440 (1964), Database Crossfire, Beilstein No. 5-24.
Howard, Provisional Patent Application No. 60/015,134 filed Mar. 29, 1996 for "Lactam Derivatives".
Andreani et al., Chemical Abstracts, vol. 113, abstract 78106, 1990.
Blake et al., Chemical Abstracts, vol. 80, abstract 26692, 1974.
Ijaz et al., Chemical Abstracts, vol. 113, abstract 97379, 1990.
Zhungietu et al., Chemical Abstracts, vol. 78, abstract 111201, 1973.
Beilstein Reg. No. 236050, Abramovitch, J. Chem. Soc., pp. 1697, 1700, 1954.
Beilstein Reg. No. 235900, Wright, J. Am. Chem. Soc., vol. 78, pp. 221, 224, 1956.
Beilstein Reg. No. 231732, Wahl, Bull. Soc. Chim. Fr, pp. 1035, 1038, 1909.
Beilstein Reg. No. 194139, Wahl, Bull. Soc. Chim. Fr., p. 1038, 1909.
Akbasak, A., and Sunar-Akbasak, B. (1992). Oncogenes: cause or consequence in the development of glial tumors. Journal of the Neurological Sciences 111, 119-133.
Arteaga, C. L., Kitten, L. J., Coronado, E. B., Jacobs, S., Kull, F. C. J., Allred, D. C., and Osborne, C. K. (1989). Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest. 84, 1418-1423.
Baserga, R. (Dec. 1994). Oncogenes and the strategy of growth factors. Cell 79, 927-930.
Baserga, R. (Jan. 1995). The insulin-like growth factor I receptor: a key to tumor growth? Cancer Research 55, 249-252.
Bolen, J. B., Rowley, R. B., Spana, C., and Tsygankov, A. Y. (1992). The Src family of tyrosine protein kinases in hemopoietic signal transduction: FASEB Journal 6, 3403-3409.
Bolen, J. B. (1993). Nonreceptor tyrosine protein kinases. Oncogene 8, 2025-2031.
Coppola, D., et al. (Jul. 1994). A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Molecular and Cellular Biology 14, 4588-4595.
Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., and De Bortoli, M. (1990). Inhibition of c-erB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5, 1001-1006.
Decker, T., and Lohmann-Matthes, M.-L. (1988). A quick and simple method for quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. of Imm. Methods 15, 61-69.
Dickson, R. B., Salomon, D. S., and Lippman, M. E. (1991). Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer. Cancer Treatment and Research 61, 249-273.
Fantl, W. J., et al. (1992). Distinct Phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 69, 413-423.
Fendly, B. M. (1990), Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HEr2
eu gene product. Cancer Research 50, 1550-1558.
Fingl, E., and Woodbury, D. M. (1975). The Pharmacological Basis of Therapeutics Chapter I, 1-46.
Floege, J. Eng, E., Young, B. A., and Johnson, R. J. (1993). Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney International 43, S-47-S-54.
Goldring, M. B., and Goldring, S. R. (1991). Cytokines and cell growth control. Critical Reviews in Eukaryotic Gene Expression 1, 301-326.
Gottardis, M. M., Robinson, S. P., and Jordan, C. B. (1988). Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifen. J. Steriod Biochem. 30, 311-314.
Honegger, A. M., et al. (1987). Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51, 199-209.
Jellinek, D., Green, L. S., and Janjic, N. (Aug. 1994), Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 33, 10450-10456.
Kendall, R. L., and Thomas, K. A. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc.Natl.Acad. Sci. 90, 10705-10709.
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
Kinsella, J. L., Grant, D. S., Weeks, B. S., and Kleinman, H.K. (1992). Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, matrigel. Experimental Cell Research 199, 56-62.
Koch, C. A., Anderson, D., Moran, M. F., Ellis. C., and Pawson, T. (1991). SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins, Science 252, 668-674.
Korc, M., et al. (1992). Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Inv. 90, 1352-60.
Korzseniewski, C., and Callewaert, D. M. (1983). An enzyme-release assay for natural cytotoxicity. Journal of Immunological Methods 64, 313-320.
Kumabe, T., et al. (1992). Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. Oncogene 7, 627-633.
Lee, B. A., and Donoghue, D. J. (1992). Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction. The Journal of Cell Biology 118, 1057-1070.
Macaulay, V. M., Everard, M. J., Teale, J. D., Trott, P. A., Van Wyk, J. J., and Smith, I. E. (1990). Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Research 50, 2511-2517.
Mariani, M., et al. (Mar. 1994). Inhibition of an
McMahon Gerald
Sun Li
Tang Peng Cho
Raymond Richard L.
Sugen Inc.
LandOfFree
3-(2'-alkoxybenzylidenyl)-2-indolinone and analogues thereof for does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-(2'-alkoxybenzylidenyl)-2-indolinone and analogues thereof for, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(2'-alkoxybenzylidenyl)-2-indolinone and analogues thereof for will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-818058